Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALXN 2030

Next Previous
Drug Profile

ALXN 2030

Alternative Names: ALXN-2030

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion AstraZeneca Rare Disease
  • Class Small interfering RNA
  • Mechanism of Action Complement C3 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal transplant rejection

Most Recent Events

  • 07 Mar 2025 Phase-II clinical trials in Renal transplant rejection in South Korea (SC) (NCT06744647)
  • 20 Dec 2024 Alexion Pharmaceuticals plans a phase II CONCORD trial for Renal transplant rejection in the US, Brazil, Canada, South Korea and Taiwan (SC) in March 2025 (NCT06744647)
  • 22 Aug 2022 Preclinical trials in Unspecified in USA (SC) before August 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top